Hyperfine reports 1st AD patients enrolled in CARE PMR observational study

Hyperfine announced that the first patients have been enrolled in the CARE PMR or Capturing ARIA Risk Equitably with Portable MR, observational study. The study is designed to assess the clinical utility and workflow benefits of Swoop system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities, ARIA, in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling…”The newly approved amyloid-targeting therapy represents a major milestone in the global fight against Alzheimer’s, bringing hope of additional years of independent living to patients. The required MRI scans to image brain abnormalities in patients receiving amyloid-targeting therapy present workflow challenges for patients and providers,” said Hyperfine, Inc. President and CEO Maria Sainz. “Patients can be safely scanned with the Swoop system wherever in a healthcare setting is most convenient, and we believe that it greatly simplifies the workflow and provides significant benefits in care efficiency and cost. We look forward to investigating its potential as a screening tool and exploring how this accessible and affordable portable MRI modality can help address the challenges of access to care and equity challenges intrinsic to new treatments for this devastating global disease.”